Page last updated: 2024-11-07

phorbolol myristate acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID99950
MeSH IDM0066814

Synonyms (13)

Synonym
nsc 278618
tpa-3-beta-ol
phma
5h-cyclopropa(3,4)benz(1,2-e)azulen-5-ol, 1,1a-beta,1b-alpha,4,4a,7a-beta,7b,8,9,9a-decahydro-4a-alpha,7b-beta,9-alpha,9a-beta-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-beta-tetramethyl-, 9a-acetate 9-myristate
phorbolol acetate myristate
phorbolol-12-myristate-13-acetate
56937-68-9
phorbolol myristate acetate
nsc278618
nsc-278618
9a-(acetyloxy)-4a,5,7b-trihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1h-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl tetradecanoate
DTXSID00972379
[13-acetyloxy-1,5,6-trihydroxy-8-(hydroxymethyl)-4,12,12,15-tetramethyl-14-tetracyclo[8.5.0.02,6.011,13]pentadeca-3,8-dienyl] tetradecanoate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Of the total 13 adverse events (n = 12), 11 were mild, 2 were moderate, and none were severe, and only 5 were considered by the investigator as possibly related to treatment."( The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression.
Barrett, J; Blotner, S; Busse-Reid, R; DeSchepper, S; Deutsch, J; Goelzer, P; Lee, L; Niu, H; Peck, R; Rueger, R; Weissgerber, G, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Differentiation of cells by PMA induced midkine, TNF-α, IL-10 and IFN-γ secretions in monocytic cells even at the lowest dosage (10 ng/ml)."( [Investigation of cytokine and midkine responses of human THP-1 leukemia cells induced by phorbol-12-Myristate-13-Acetate (PMA) at different concentrations and times].
Biriken, D; Yazıhan, N; Yılmaz, Ş, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (308)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (2.60)18.7374
1990's10 (3.25)18.2507
2000's144 (46.75)29.6817
2010's138 (44.81)24.3611
2020's8 (2.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.95 (24.57)
Research Supply Index5.76 (2.92)
Research Growth Index5.71 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.64%)5.53%
Reviews2 (0.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other310 (98.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]